Diffusion Pharmaceuticals Inc. (DFFN) financial statements (2020 and earlier)

Company profile

Business Address 2020 AVON COURT
CHARLOTTESVILLE, VA 22902
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1468581113
Cash and cash equivalents1468581113
Other undisclosed current assets0111111
Total current assets:1579691214
Noncurrent Assets
Operating lease, right-of-use asset0000
Property, plant and equipment0000000
Intangible assets, net (including goodwill)999991116
Goodwill     37
Intangible assets, net (excluding goodwill)9999999
Other noncurrent assets0000000
Total noncurrent assets:99101091216
TOTAL ASSETS:24161916182430
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2111111
Accounts payable1100000
Accrued liabilities0101111
Debt0000   
Total current liabilities:2111111
Noncurrent Liabilities
Long-term debt and lease obligation0000   
Operating lease, liability0000
Liabilities, other than long-term debt2   222
Deferred tax liabilities, net222
Deferred income tax liabilities2   
Other undisclosed noncurrent liabilities 122   
Total noncurrent liabilities:2122222
Total liabilities:4333333
Stockholders' equity
Stockholders' equity attributable to parent20141613162127
Common stock0000000
Additional paid in capital11210110196969595
Accumulated deficit(92)(88)(85)(83)(80)(74)(68)
Total stockholders' equity:20141613162127
TOTAL LIABILITIES AND EQUITY:24161916182430

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(3)(3)(3)(3)(6)(7)(3)
Operating loss:(3)(3)(3)(3)(6)(7)(3)
Other undisclosed loss from continuing operations before equity method investments, income taxes    (0)  
Loss from continuing operations before equity method investments, income taxes:(3)(3)(3)(3)(6)(7)(3)
Other undisclosed income from continuing operations before income taxes0000000
Loss from continuing operations before income taxes:(3)(3)(3)(3)(6)(7)(3)
Income tax expense (benefit)(1)000(0)00
Net loss attributable to parent:(4)(3)(2)(3)(6)(7)(3)
Preferred stock dividends and other adjustments    (8)  
Other undisclosed net income available to common stockholders, basic    8  
Net loss available to common stockholders, diluted:(4)(3)(2)(3)(6)(7)(3)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(4)(3)(2)(3)(6)(7)(3)
Comprehensive loss, net of tax, attributable to parent:(4)(3)(2)(3)(6)(7)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: